当前位置: X-MOL 学术Egypt. J. Bronchol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Non-invasive IGFBP1, IGFBP2 biomarkers as predictors and outcomes of usual interstitial pneumonia (UIP) therapeutic response
The Egyptian Journal of Bronchology Pub Date : 2021-01-18 , DOI: 10.1186/s43168-020-00050-x
M. Habeb , S. Embarak , A. Fathy , M. Zalat

Usual interstitial pneumonia (UIP) is a fatal disease that is associated with poor prognosis and survival. Several growth factors such as IGFs (insulin-like growth factors) and IGFBPs (insulin-like growth factor binding proteins) seem to take part to this pathogenesis. Pirfenidone is an immunosuppressant drug that is thought to have anti-inflammatory and anti-fibrotic effects both in vitro and in vivo. To assess IGFBP1 and IGFBP2 as non-invasive biomarkers for prediction and outcomes of UIP clinical activity and therapeutic response to the anti-fibrotic pirfenidone. Serum levels of IGFBP1 and IGFBP2 were significantly higher in the UIP group than in the healthy subjects (p ≤ 0.005). After 6 months therapy, UIP patients were divided into 2 groups according to improvement in MRC dyspnea grading into clinically improved and non-improved groups. 6MWT and SPaO2 were significantly improved in the clinically improved group compared to the non-improved one with no differences as regards other parameters (p < 0.0001). Both IGFBP1 and IGFBP2 were significantly decreased in serum while only IGFBP2 was decreased in BAL of all UIP after completing 12 months therapy. IGFBP1 and IGFBP2 were increased in active UIP patients and reduced after 12 months anti-fibrosing therapy. IGFBPs may be promising biomarkers and predictors of response to therapy in UIP.

中文翻译:

非侵入性IGFBP1,IGFBP2生物标志物可作为通常的间质性肺炎(UIP)治疗反应的预测因子和结果

通常的间质性肺炎(UIP)是一种致命的疾病,与不良的预后和生存有关。几种生长因子,例如IGF(胰岛素样生长因子)和IGFBP(胰岛素样生长因子结合蛋白)似乎参与了这一发病机理。吡非尼酮是一种免疫抑制剂,被认为在体外和体内均具有抗炎和抗纤维化作用。评估IGFBP1和IGFBP2作为非侵入性生物标志物,以预测UIP临床活性和对抗纤维化吡非尼酮的治疗反应的预测和结果。UIP组的血清IGFBP1和IGFBP2显着高于健康受试者(p≤0.005)。经过6个月的治疗后,UIP患者根据MRC呼吸困难的改善分为2组,分为临床改善组和未改善组。与未改善组相比,临床改善组的6MWT和SPaO2显着改善,其他参数无差异(p <0.0001)。完成12个月的治疗后,所有UIP的BAL血清中IGFBP1和IGFBP2均显着降低,而IGFBP2仅降低。活动性UIP患者的IGFBP1和IGFBP2升高,抗纤维化治疗12个月后降低。IGFBPs可能是有希望的生物标志物和UIP治疗反应的预测因子。活动性UIP患者的IGFBP1和IGFBP2升高,抗纤维化治疗12个月后降低。IGFBPs可能是有希望的生物标志物和UIP治疗反应的预测因子。活动性UIP患者的IGFBP1和IGFBP2升高,抗纤维化治疗12个月后降低。IGFBPs可能是有希望的生物标志物和UIP治疗反应的预测因子。
更新日期:2021-01-19
down
wechat
bug